The U.S. Food and Drug Administration has recently expanded approval for tislelizumab-jsgr (Tevimbra) to include treatment in first-line advanced esophageal squamous cell carcinoma (ESCC) in combination with chemotherapy. Tislelizumab-jsgr (Tevimbra), in combination with platinum-based chemotherapy, is now available as a first-line treatment for adults with unresectable or metastatic ESCC whose tumors express PD-L1. This approval expands treatment options for patients with advanced ESCC, addressing a critical need for more effective therapies.
Key Benefits in the Phase 3 Randomized, Placebo-Controlled, Double-Blind, Global Study
- Improved Survival:
- The tislelizumab combination significantly extended overall survival compared to chemotherapy alone. Patients receiving the new treatment lived a median of 17.2 months, versus 10.6 months for those on chemotherapy only.
- Patients with PD-L1 positive tumors who received tislelizumab plus chemotherapy lived significantly longer, with a median survival of 16.8 months compared to 9.6 months for those on chemotherapy alone. This represents a 34% lower risk of death, marking a substantial advancement in treatment for newly diagnosed advanced esophageal cancer.
- Better Response: 63% of patients responded to the tislelizumab combination, compared to 42% for chemotherapy alone.
Read more about tislelizumab and the Phase 3 RATIONALE 306 study here.
What Patients Should Know
- Eligibility: The treatment is for adults with unresectable or metastatic ESCC whose tumors express PD-L1.
- Administration: Tislelizumab is given intravenously every three weeks, along with chemotherapy.
- Side Effects: Common side effects include decreased blood cell counts and anemia. Patients should discuss potential risks with their healthcare provider.
About Tislelizumab
Tislelizumab is a type of precision cancer medicine. This humanized IgG4 anti-PD-1 monoclonal antibody was designed specifically to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells.
The expanded indication of tislelizumab for front-line treatment offers renewed hope for patients facing advanced esophageal cancer, potentially extending lives and improving quality of life.
References
Xu J, Kato K, Raymond E, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2023;24(5):483-495.
